Related Experiment Videos
[Cell therapy to treat heart failure]
F Mouquet1, S Susen, E Van Belle
1Service de cardiologie C, hôpital cardiologique de Lille, CHR et université de Lille, boulevard du Professeur-Leclercq, 59037 cedex, Lille, France. fmouquet@libertysurf.fr <fmouquet@libertysurf.fr>
La Revue De Medecine Interne
|June 20, 2003
Summary
Cell therapy offers a promising new treatment for systolic heart failure after myocardial infarction. Early clinical trials show the feasibility of autologous skeletal myoblast implantation, with further studies underway.
Area of Science:
- Cardiology
- Regenerative Medicine
- Cell Therapy
Context:
- Systolic heart failure, often resulting from myocardial infarction, significantly impairs left ventricular function.
- Despite medical advancements, the prognosis for heart failure remains poor, with a 5-year survival rate of only 30%.
- Current treatments primarily delay disease progression, and heart transplantation is limited to a select few.
Purpose:
- To explore cell therapy as a novel, potentially non-invasive treatment for post-myocardial infarction systolic heart failure.
- To provide a treatment option accessible to a broader patient population compared to heart transplantation.
Summary:
- A Phase I clinical trial in France demonstrated the feasibility of intracardiac autologous skeletal myoblast implantation for systolic heart failure.
- Experimental models showed promising results, supporting further clinical investigation.
- Ongoing studies in Europe and the USA are evaluating diverse cell types and delivery methods.
Impact:
- Cell therapy holds potential to improve outcomes for patients with systolic heart failure.
- Successful clinical trials could lead to new therapeutic strategies for a common and severe cardiac condition.
- Further research and Phase II trials are anticipated to establish the efficacy and safety of this approach.